Breaking News Instant updates and real-time market news.

FATE

Fate Therapeutics

$12.81

-0.775 (-5.71%)

18:34
11/11/18
11/11
18:34
11/11/18
18:34

Fate Therapeutics announces dose-escalation clinical data of FATE-NK100

Fate Therapeutics announced new clinical data for FATE-NK100, an investigational, first-in-class, allogeneic donor-derived natural killer cell cancer immunotherapy, and provided a regulatory update on the development of FT500, a universal, off-the-shelf NK cell product candidate derived from a master induced pluripotent stem cell line, on November 10, 2018. Twenty heavily pre-treated subjects, each presenting with progressive disease at the time of enrollment, have been treated with FATE-NK100 in the dose-escalation phases of three Phase 1 clinical trials. As of a October 22, 2018 data cutoff, one-month follow-up data were available on fourteen subjects, with clinical benefit indicated in seven of these fourteen subjects: In the DIMENSION study for the treatment of advanced solid tumors, one subject at the second dose level and two subjects at the third dose level treated with a single intravenous infusion of FATE-NK100 in the monotherapy regimen had stable disease at one month. These two subjects at the third dose level were each subsequently treated with a second dose of FATE-NK100 and remain on study with ongoing disease control. The study is currently enrolling at the third dose level in the monotherapy regimen, at the second dose level in the cetuximab combination regimen and at the run-in dose level in the trastuzumab combination regimen. In the APOLLO study for the treatment of recurrent ovarian cancer, one subject treated with a single intraperitoneal infusion of FATE-NK100 at the second dose level had stable disease at one month. The subject was subsequently treated with a second dose of FATE-NK100 and maintained disease control for 6.2 months. The study is currently enrolling at the third dose level. In the VOYAGE study for the treatment of refractory or relapsed acute myelogenous leukemia, all three subjects treated with a single intravenous infusion of FATE-NK100 at the second dose level showed complete clearance of leukemic blasts in the bone marrow and achieved a morphologic leukemia-free state at Day 14 following treatment. Each of these three subjects received a single dose of FATE-NK100 only, and the anti-leukemic response in each of these subjects was transient. The study is currently enrolling at the second dose level. No dose limiting toxicities related to FATE-NK100 were reported. One serious adverse event related to FATE-NK100 was reported in the APOLLO study. In addition, the company announced that adventitious agents testing of the master iPSC bank for the clinical production of FT500, a universal, off-the-shelf NK cell product candidate, has been completed. The FT500 master iPSC bank was found to be free of adventitious agents as determined by in vivo and in vitro testing. The company has submitted these results to the U.S. Food and Drug Administration in furtherance of the agency's review of the company's FT500 Investigational New Drug application. Upon allowance by the FDA of the FT500 IND, the company plans to initiate Phase 1 clinical testing of FT500 as a monotherapy and in combination with checkpoint inhibitor therapy for the treatment of advanced solid tumors. This first-in-human study is expected to evaluate the safety and tolerability of multiple doses of FT500 in multiple dosing cycles.

  • 27

    Nov

  • 30

    Nov

  • 01

    Dec

FATE Fate Therapeutics
$12.81

-0.775 (-5.71%)

09/18/18
WELS
09/18/18
NO CHANGE
WELS
Fate Therapeutics platform validated with Ono deal, says Wells Fargo
Wells Fargo analyst Jim Birchenough reiterates an Outperform rating on Fate Therapeutics after the company announced a deal with Ono Pharmaceuticals for induced pluripotent stem cell derived CAR T Therapeutics. The deal validates Fate's iPSC platform, should increase confidence in near term investigational new drug application clearance and provides support for its accelerating pipeline development, Birchenough tells investors in a research note. He reiterates an Outperform rating on Fate Therapeutics.
09/18/18
PIPR
09/18/18
NO CHANGE
Target $25
PIPR
Overweight
Fate Therapeutics price target raised to $25 from $20 at Piper Jaffray
After Fate Therapeutics announced a collaboration with ONO Pharmaceutical for the joint development and commercialization of two off-the-shelf CAR-T cell product candidates, Piper Jaffray analyst Edward Tenthoff said he likes the deal as it expands Fate's iPSC CAR-T pipeline while also giving the company $70M in near-term funding. Following the collaboration pact, Tenthoff increased his price target on Fate shares to $25 and reiterated an Overweight rating.
09/25/18
PIPR
09/25/18
NO CHANGE
Target $23
PIPR
Overweight
Fate Therapeutics price target lowered to $23 from $25 at Piper Jaffray
Piper Jaffray analyst Edward Tenthoff lowered his price target for Fate Therapeutics to $23 to account for dilution from the equity issuance. He estimates Fate now holds proforma cash of $223M to advance and expand its clinical pipeline of off-the-shelf Natural Killer cell and CAR-T therapies. The analyst reiterates an Overweight rating on the shares.
11/05/18
JEFF
11/05/18
INITIATION
Target $17
JEFF
Buy
Fate Therapeutics initiated with a Buy at Jefferies
Jefferies analyst Biren Amin started Fate Therapeutics with a Buy rating and $17 price target. Natural killer cells possess advantageous cytotoxic properties distinct from T cells, and have demonstrated clinical efficacy against select cancer types, Amin tells investors in a research note. The analyst says Fate "offers a unique and potentially disruptive approach."

TODAY'S FREE FLY STORIES

PINS

Pinterest

$24.46

(0.00%)

13:04
04/20/19
04/20
13:04
04/20/19
13:04
Periodicals
Pinterest stock is hot after IPO, investors should keep cool, Barron's says »

Pinterest priced its IPO…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Apr

HUM

Humana

$240.65

7.645 (3.28%)

, CI

Cigna

$148.95

3.46 (2.38%)

12:51
04/20/19
04/20
12:51
04/20/19
12:51
Periodicals
Health insurers stocks now look like a buy, Barron's says »

Investing in health…

HUM

Humana

$240.65

7.645 (3.28%)

CI

Cigna

$148.95

3.46 (2.38%)

ANTM

Anthem

$239.63

3.38 (1.43%)

UNH

UnitedHealth

$221.74

4.93 (2.27%)

CVS

CVS Health

$52.62

0.08 (0.15%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Apr

  • 24

    Apr

  • 30

    Apr

  • 01

    May

  • 01

    May

  • 02

    May

  • 07

    May

  • 15

    May

  • 16

    May

  • 19

    May

  • 22

    May

  • 23

    May

  • 29

    May

  • 18

    Jun

  • 13

    Nov

TSLA

Tesla

$273.25

2.13 (0.79%)

12:49
04/20/19
04/20
12:49
04/20/19
12:49
Hot Stocks
Tesla says four board members agreed to not stand for re-election »

Tesla disclosed late…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Apr

  • 24

    Apr

AMD

AMD

$27.68

0.18 (0.65%)

, INTC

Intel

$58.49

-0.08 (-0.14%)

12:43
04/20/19
04/20
12:43
04/20/19
12:43
Periodicals
Wall Street cheered Intel decision to exit 5G modem business, Barron's says »

Apple (AAPL) and Qualcomm…

AMD

AMD

$27.68

0.18 (0.65%)

INTC

Intel

$58.49

-0.08 (-0.14%)

QCOM

Qualcomm

$79.89

0.8 (1.01%)

AAPL

Apple

$203.83

0.69 (0.34%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 30

    Apr

  • 30

    Apr

  • 01

    May

  • 08

    May

  • 15

    May

  • 16

    May

  • 03

    Jun

  • 03

    Jun

SAM

Boston Beer

$266.90

0.89 (0.33%)

12:37
04/20/19
04/20
12:37
04/20/19
12:37
Periodicals
'Happy hour' might be over for Boston Beer, Barron's says »

Boston Beer's shares…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Apr

  • 16

    May

SPOT

Spotify

$139.53

1.88 (1.37%)

12:30
04/20/19
04/20
12:30
04/20/19
12:30
Periodicals
Spotify stock 'risky' as music industry not changing fast enough, Barron's says »

Spotify might end up…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Apr

BA

Boeing

$380.02

2.48 (0.66%)

, HRL

Hormel Foods

$40.38

-0.37 (-0.91%)

08:33
04/20/19
04/20
08:33
04/20/19
08:33
On The Fly
Week in review: How Trump's policies moved stocks »

Catch up on the top…

BA

Boeing

$380.02

2.48 (0.66%)

HRL

Hormel Foods

$40.38

-0.37 (-0.91%)

PPC

Pilgrim's Pride

$25.79

0.03 (0.12%)

SAFM

Sanderson Farms

$141.70

-2.17 (-1.51%)

TSN

Tyson Foods

$73.49

0.2 (0.27%)

CCL

Carnival

$53.64

-0.92 (-1.69%)

RCL

Royal Caribbean

$121.00

-2.245 (-1.82%)

NCLH

Norwegian Cruise Line

$56.93

-0.925 (-1.60%)

WFTBF

West Fraser Timber

$0.00

(0.00%)

IFSPF

Interfor

$0.00

(0.00%)

CFPZF

Canfor

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Apr

  • 29

    Apr

  • 01

    May

  • 02

    May

  • 06

    May

  • 18

    May

  • 28

    May

  • 29

    May

  • 29

    May

  • 05

    Jun

  • 13

    Nov

MSM

MSC Industrial

$83.37

-0.44 (-0.52%)

04:55
04/20/19
04/20
04:55
04/20/19
04:55
Conference/Events
MSC Industrial management to meet with William Blair »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Apr

  • 21

    Apr

  • 22

    Apr

  • 23

    Apr

  • 24

    Apr

  • 05

    Jun

  • 13

    Nov

KFS

Kingsway Financial

$2.30

-0.14 (-5.74%)

19:48
04/19/19
04/19
19:48
04/19/19
19:48
Hot Stocks
Kingsway Financial announces receipt of notification letter from NYSE »

Kingsway Financial…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AWK

American Water

$104.63

2.32 (2.27%)

19:46
04/19/19
04/19
19:46
04/19/19
19:46
Hot Stocks
American Water signs contract to acquire East Pasadena Water Company »

California American…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    May

  • 10

    May

FSNN

Fusion

$0.24

0.0048 (2.01%)

19:45
04/19/19
04/19
19:45
04/19/19
19:45
Hot Stocks
Fusion sees being delisted following receipt of Nasdaq delisting notice »

Fusion announced that it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    May

  • 30

    May

PSA

Public Storage

$217.43

0.81 (0.37%)

19:42
04/19/19
04/19
19:42
04/19/19
19:42
Hot Stocks
Public Storage announces change of Chief Legal Officer »

Public Storage announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Apr

  • 02

    May

  • 04

    Jun

V

Visa

$160.14

-0.33 (-0.21%)

19:40
04/19/19
04/19
19:40
04/19/19
19:40
Hot Stocks
Visa board elects Visa CEO Al Kelly as Chair »

Visa announced that its…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Apr

  • 09

    May

  • 29

    May

  • 05

    Jun

NAVB

Navidea

$0.17

0.0001 (0.06%)

19:39
04/19/19
04/19
19:39
04/19/19
19:39
Hot Stocks
Navidea announces one-for-twenty reverse stock split »

Navidea…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TISA

Top Image Systems

$0.84

-0.0069 (-0.81%)

19:37
04/19/19
04/19
19:37
04/19/19
19:37
Hot Stocks
Top Image sees voluntarily delisting to be complete before Nasdaq deadline »

Top Image Systems…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FCPT

Four Corners Property Trust

$28.17

0.49 (1.77%)

19:33
04/19/19
04/19
19:33
04/19/19
19:33
Hot Stocks
Four Corners Property Trust acquires restaurant properties for $2.6M »

Four Corners Property…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Apr

PRK

Park National

$93.98

-2.72 (-2.81%)

19:32
04/19/19
04/19
19:32
04/19/19
19:32
Earnings
Park National reports Q1 EPS $1.62, two estimates $1.61 »

Commercial loans grew…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Apr

  • 29

    May

STNE

StoneCo

$26.50

-8.25 (-23.74%)

19:29
04/19/19
04/19
19:29
04/19/19
19:29
Hot Stocks
StoneCo says latest incentive offers from competitors don't change strategy »

StoneCo released a CEO…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Jun

GPIC

Gaming Partners

$13.09

(0.00%)

19:24
04/19/19
04/19
19:24
04/19/19
19:24
Hot Stocks
Gaming Partners sees acquisition by Angel closing on May 1 »

Gaming Partners…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SCHW

Charles Schwab

$45.57

-0.53 (-1.15%)

17:04
04/19/19
04/19
17:04
04/19/19
17:04
Conference/Events
Charles Schwab to hold a webcast »

Management holds a 2019…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

  • 15

    May

12:45
04/19/19
04/19
12:45
04/19/19
12:45
General news
Breaking General news story  »

Week of 4/19 Baker-Hughes…

MMNFF

MedMen

$0.00

(0.00%)

11:13
04/19/19
04/19
11:13
04/19/19
11:13
Hot Stocks
MedMen announces resignations of COO and General Counsel »

MedMen Enterprises…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TKC

Turkcell

$5.49

-0.175 (-3.09%)

11:08
04/19/19
04/19
11:08
04/19/19
11:08
Hot Stocks
Turkcell sees conclusion of $4.2B lawsuit against MTN this year »

The following statement…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FCCY

1st Constitution Bancorp

$18.07

-0.14 (-0.77%)

11:05
04/19/19
04/19
11:05
04/19/19
11:05
Earnings
1st Constitution Bancorp reports Q1 EPS 39c, two estimates 36c »

Robert Mangano, President…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

QUMU

Qumu

$2.83

-0.035 (-1.22%)

11:03
04/19/19
04/19
11:03
04/19/19
11:03
Hot Stocks
Qumu announces death of director Thomas Madison »

Qumu Corporation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    May

  • 09

    May

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.